CardioDx to Present at Wedbush PacGrow Life Sciences Management Access Conference
PALO ALTO, Calif. – August 14, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced its participation at the Wedbush PacGrow Life Sciences Management Access Conference to be held at the Le Parker Meridien Hotel in New York City. David Levison, the company’s President and Chief Executive Officer, will provide an overview of CardioDx and of Corus® CAD, the only clinically validated gene expression test for obstructive coronary artery disease. The presentation will take place on Wednesday, August 15 at 8:00 a.m. ET at the Le Parker Meridien Hotel in New York City.
With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient’s symptoms are due to obstructive coronary artery disease (CAD), enabling many patients to avoid unnecessary invasive testing and exposure to imaging-related radiation risks or imaging agent intolerance. The test has been clinically validated in multiple independent patient cohorts, including two prospective, multicenter U.S. trials, PREDICT and COMPASS. Additionally, a retrospective, multicenter chart review study and the prospective IMPACT trial at Vanderbilt University demonstrated that Corus CAD use yielded significant and clinically relevant changes in patient management decisions in both primary care and cardiology settings.
The company recently announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the Corus CAD gene expression test for the evaluation of patients presenting with typical and atypical symptoms suggestive of coronary artery disease. With this decision, the Corus CAD gene expression test is now a covered benefit for more than 40 million Medicare enrollees in the U.S.
Corus CAD has been recognized by The Wall Street Journal’s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME’s Top Ten Medical Breakthroughs.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.